Illinois And Dreieich

ABBOTT PARK, Illinois and DREIEICH, Germany, June 21, 2011 - BT-061 in clinical development for the treatment of RA and psoriasis Abbott and Biotest AG today announced a global agreement to develop and commercialize BT-061, a novel anti-CD4 antibody for the treatment of rheumatoid arthritis (RA) and psoriasis.